We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Senate supporters of the reimportation of prescription drugs quietly introduced a bill last week that would allow imports from 25 industrialized countries, effectively bypassing a certain committee roadblock in favor of what they consider better odds of passage on the Senate floor.
Pharmaceutical manufacturers yesterday denied they will reap billions of dollars in additional profits under the new Medicare prescription drug law, saying the benefit will have little overall effect on revenues or research and development efforts.
In what could become a trend among states trying to lower drug prices, South Dakota lawmakers this week passed legislation requiring pharmaceutical benefits managers (PBMs) to reveal the rebates and payments they receive from pharmaceutical firms.
In an effort to quell the rising call for reimportation, as well the increasingly loud whispers on Capitol Hill about price controls, the chairman and chief executive officer of Schering-Plough yesterday announced a three-part proposal to help uninsured Americans that includes access to free prescription drugs.
Generic drugmaker Mylan Laboratories has rejoined Pennsylvania’s $400 million prescription drug discount program on the condition that state officials work to lower the required rebate on generic drugs to 11 percent.
Unless major changes are made, Canadian generic drugmakers say they are unlikely to take advantage of a proposed drug export law that would let them break patents on brand drugs sent to poor countries facing health emergencies such as AIDS, malaria and tuberculosis.
A campaign funded by the National Institutes of Health (NIH) to educate doctors about the option of prescribing low-cost alternatives to antihypertensive drugs is taking direct aim at the bottom lines of pharmaceutical manufacturers.
Reversing an earlier decision, generic drugmaker Mylan Laboratories has rejoined Pennsylvania’s $400 million prescription drug discount program on the condition that state officials work to lower the required rebate on generic drugs to 11 percent.
The cross hairs of a campaign funded by the National Institutes of Health (NIH) to educate doctors about the option of prescribing low-cost alternatives to antihypertensive drugs are centered squarely on the bottom lines of pharmaceutical manufacturers.
Overall prescription drug sales in the U.S. grew 11.5 percent to $216.4 billion last year despite challenges from new OTC products, concerns about hormone replacement therapies and the reimportation of drugs from Canada, according to IMS Health.